|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum显示文摘草药的药最近在美国作为导致药的肝损害(DILI ) 的第二个很普通的原因被认出了。然而,识别一些植物的 DILI 诱发性的可靠方法例如 Heshouwu (蓼 multiflorum 的弄干的根) ,留下缺乏。在这研究,有肝机能障碍和 Heshouwu DILI 的 147 个报导文学的案例的 12 307 个住院病人的一个总数被屏蔽。一个一般算法仅仅显示了那 22.5%(9/40 ) 并且(45/147 ) 分别地, 30.6% 所有住院和文学案例报告表明 Heshouwu 的 DILI 诱发性的高概率。由对比,(19/20 )95% 生药学,植物化学,和 metabolomic 有希望地调查的所有情况测试展出高度可能的诱发性,包括不正确地以前被归因的一个病人和从由 pharmacognostic 证据的 Heshouwu 诱发性被排除的一个案例。污染也是的毒素(重金属,杀虫剂,和 mycotoxins ) 从 Heshouwu DILI 诱发性排除了。为 Heshouwu DILI 诊断地址安全的这些屏蔽方法的客观性担心考虑包含芪的草药的药和饮食的补充。 | Jiabo Wang Zhijie Ma Ming Niu Yun Zhu Qingsheng Liang Yanling Zhao Jingyuan Song Zhaofang Bai Yaming Zhang Ping Zhang Na Li Yakun Meng Qi Li Lushan Qin Guangju Teng Junling Cao Baosen Li Shilin Chen Yonggang Li Zhengsheng Zou Honghao Zhou Xiaohe Xiao | 2015 | Frontiers of Medicine2015，9，4： | 47 |
| 2 | Enhancing both selectivity and coking-resistance of a single-atom Pd1/C3N4 catalyst for acetylene hydrogenation显示文摘选择加氢是在化学升级的一个重要工业催化过程,在因为他们的高加氢活动,基于 Pd 的催化剂广泛地被使用的地方。然而,因为重焦炭形成,差的选择和短催化剂一生是主要担心。在这个工作,原子地驱散 Pd 原子成功地在 graphitic 碳氮化物上被综合(g-C 3 用原子层免职的 N 4) 。没有 Pd nanoparticle (NP ) ,改正错误的高角度的环形的黑暗地的扫描传播电子显微镜学(HAADF 茎) 证实了孤立的 Pd 原子的主导的存在形成。在在过量乙烯的乙炔的选择加氢期间, g-C 3 N 4-supported Pd NP 催化剂比常规 Pd/Al 2 O 3 和 Pd/SiO 2 催化剂。在原处, X 光检查光致核裂变光谱学表明可观的费用从 Pd NP 转到 g-C 3 N 4 多半在催化表演改进起一个重要作用。更给人深刻印象地,单个原子的 Pd 1/C3 N 4 催化剂展出了两种更高的乙烯选择和更高的 coking 抵抗。我们的工作证明单个原子的 Pd 催化剂是在加氢反应改进选择和焦炭抵抗的一个有希望的候选人。 | Xiaohui Huang Yujia Xia Yuanjie Cao Xusheng Zheng Haibin Pan Junfa Zhu Chao Ma Hengwei Wang Junjie Li Rui You Shiqiang Wei Weixin Huang Junling Lu | 2017 | Nano Research2017，10，4： | 16 |
| 3 | SEUSS and PIF4 Coordinately Regulate Light and Temperature Signaling Pathways to Control Plant Growth显示文摘 | Junling Huai Xinyu Zhang dialong Li Tingting Ma Ping Zha Yanjun Jing Rongcheng Lin | 2018 | Molecular Plant2018，11，7： | 15 |
| 4 | Detection of ALK translocation in non-small cell lung carcinoma(NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1,504 Chinese Han patients显示文摘Objective: The novel fully automated immunohistochemistry(IHC) assay-Ventana anaplastic lymphoma kinase(ALK)-D5F3 for screening ALK rearrangements has been approved by China's Food and Drug Administration in 2013, our previous study disclosed a highly specificity and sensitivity nearly 100%, and its efficacy needs to be evaluated in a large cohort of primary lung adenocarcinoma patients, and to compare clinicopathological features with ALK(+) and ALK(-) lung adenocarcinoma.Methods: A total of 1,504 consecutive surgical lung adenocarcinoma cases of Chinese Han population were collected and re-diagnosed according to the 2011 multidisciplinary classification of lung adenocarcinoma.Fully automated Ventana ALK-D5F3 IHC staining with a binary scoring was adopted to evaluate staining and correlated with clinicopathological characters, including age, sex, differentiation degree, histological subtype, lymph node metastasis, and clinical staging.ALK(+) patients were followed-up, and targeted therapy of ALKinhibitors was adopted and observed in patients with stage Ⅳ according to the NCCN guideline.Results: ALK positive adenocarcinomas were identified in 6.6% of the surgically resected 1,504 NSCLCs, and significantly younger than the negative group(P<0.05).Mucinous adenocarcinoma(28.2%) was determined to be predominant in ALK(+) cases, followed by the solid type(11.7%), specific type(6.8%), papillary type(5.6%), acinar type(5.5%), and lepidic type(3.1%), and the differences were statistically significant(χ~2=42.011, P<0.05).ALK(+) adenocarcinoma with lymph node metastasis(10.8%) were significantly higher than that without lymph node metastasis(4.5%)(χ~2=19.809, P<0.05); and ALK(+) in phase Ⅳ(20%) was significantly higher than phase Ⅲ(12.9%), phase Ⅱ(4.2%), phase Ⅰ(4.5%), and phase 0(0)(χ~2=36.068, P<0.05).Multivariate logistic regression disclosed that patient age, AJCC staging, and histological mucinous subtype were correlated with ALK positive staining(OR=0.959, 1.578, 5.036, respectively).Sixty eight patients had followed-up results, five patients out of which primarily diagnosed or progressed into Stage Ⅳ benefited well from targeted therapy with Crizotinib.Conclusions: The ALK fusion protein was seen in 6.6% Chinese NSCLC patients, and mostly seen in younger, clinically higher staging, mucinous and solid predominant adenocarcinoma.Clinical trials in patients of Stage Ⅳ confirmed that ALK-D5F3 Ventana IHC is serviceable in screening ALK-positive candidates for molecular targeted therapy. | Lin Yang Yun Ling Lei Guo Di Ma Xuemin Xue Bingning Wang Junling Li Jianming Ying | 2016 | Chinese Journal of Cancer Research2016，28，5： | 8 |
| 5 | Velvet antler polypeptide is able to induce differentiation of neural stem cells towards neurons in vitro显示文摘OBJECTIVE: To investigate the neural differentiation capacity of water extraction of velvet antler.METHODS: Velvet antler(Cervus Nippon Temminck) polypeptide(VAP) was used to differentiate neural stem cells(NSCs) towards neurons in the study. Firstly, we obtain the polypeptides of VAP by water extraction. Secondly, we observed the morphology, assayed the factors in the media by enzyme-linked immunosorbent assay, and detected the special neural molecules by immuno fl uorescence staining. NSCs were cultured on the cell climbing film. After neuronal differentiation, differentiated NSCs were mounted for immunocytochemistry with immunofluorescence technique.RESULTS: The differentiating cells look like neuron,some special factors, such as Glial cell line-derived neurotrophic factor, nerve growth factor, in the media can be detected while differentiated neuron-like cells can express the special neural molecules.CONCLUSION: Differentiation of NSCs towards neurons can be induced by velvet antler polypeptide. | Zhang Lihong Zhuang Zhihong Sun Yanan Ma Shuhua Yang Weifeng Lei Hongtao Zuo Junling Ouyang Jingfeng Wang Yi | 2017 | Journal of Traditional Chinese Medicine2017，37，3： | 8 |
| 6 | Bamboo Leaf and Pollen Fossils from the Late Miocene of Eastern Zhejiang,China and their Phytogeological Significance显示文摘Fossil bamboo leaves and pollen from Upper Miocene deposits of the Shengxian Formation in Tiantai and Ninghai counties,eastern Zhejiang,China represent a rare record in Asia.The distinctive pseudopetiole and parallel venation of the leaf blades and the clearly thickened annulus of the pollen aperture place them in the subfamily Bambusoideae.Morphological analysis supports the determination of these fossil leaves as belonging to the genus Bambusium and two new species are described.Bambusium latipseudopetiolus Q.J.Wang et B.N.Sun sp.nov.has a distinctly wide pseudopetiole of 0.23 cm in width and 0.40 cm in length,several vascular bundles on parallel veins,and 5–8 lateral veins on both sides of the midrib.Bambusium longipseudopetiolus Q.J.Wang et B.N.Sun sp.nov.has a distinctly long pseudopetiole of 0.60 cm in length and 0.10 cm in width,several vascular bundles on the pseudopetiole,and 6 lateral veins on both sides of the midrib.Pollen grains from the same layer provide additional evidence of bamboos.They are characterized by 32.0–51.0 μm in diameter,a round pore 3.0–4.0 μm in diameter with a broad thickened annulus 2.5–3.5 μm around,and several conspicuous secondary folds on the exine surface.The morphological analysis leads to their assignment to Graminidites bambusoides Stuchlik.These fossils are important for the study of bamboo phytogeography in China.They demonstrate that there were bamboos growing in southeastern China during the Late Miocene and that bamboos in Zhejiang begin to diversify no later than the Late Miocene.In combination with bamboo fossils from other places,it seems that bamboos had a wide distribution across southern China during the Miocene,ranging from southwestern Yun'nan to southeastern Zhejiang. | WANG Qiujun MA Fujun YANG Yi DONG Junling WANG Haofei LI Ruiyun XU Xiaohui SUN Bainian | 2014 | Acta Geologica Sinica(English Edition)2014，88，4： | 7 |
| 7 | Estimating epidemic exponential growth rate and basic reproduction number显示文摘The initial exponential growth rate of an epidemic is an important measure of the severeness of the epidemic,and is also closely related to the basic reproduction number.Estimating the growth rate from the epidemic curve can be a challenge,because of its decays with time.For fast epidemics,the estimation is subject to over-fitting due to the limited number of data points available,which also limits our choice of models for the epidemic curve.We discuss the estimation of the growth rate using maximum likelihood method and simple models. | Junling Ma | 2020 | Infectious Disease Modelling2020，5，1： | 7 |
| 8 | Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment显示文摘Objective: Crizotinib is recommended as the first-line therapy for advanced anaplastic lymphoma kinase(ALK)-positive non-small-cell lung cancer(NSCLC). Despite its initial efficacy, patients ultimately acquire resistance to crizotinib within 1 year. In such patients, the optimal sequential therapy after crizotinib treatment remains unknown. This study explored which sequential therapy option confers the greatest benefit.Methods: A total of 138 patients with advanced ALK-positive NSCLC resistant to crizotinib were studied. Based on patterns of disease progression of metastases, patients were divided into 3 groups: brain progression, non-liver progression, and liver progression. Sequential therapies included crizotinib continuation plus local therapy, nextgeneration ALK inhibitors(ALKi's), and chemotherapy. The primary endpoint was overall survival(OS) from the time of crizotinib resistance to death or last follow-up.Results: The 138 patients included 64 cases with progression in brain, 57 cases in non-liver sites and 17 cases in liver. A significant difference in OS was observed among the distinct progression pattern(median OS, 25.4 months in brain, 15.8 months in non-liver, and 10.8 months in liver, respectively, P=0.020). The difference in OS among sequential therapies was statistically significant in the non-liver progression group(median OS, 27.6 months with next-generation ALKi's, 13.3 months with crizotinib continuation, and 10.8 months with chemotherapy,respectively, P=0.019). However, crizotinib continuation plus local therapy seems to provide non-inferior median OS compared with next-generation ALKi's for patients with brain progression(median OS, 28.9 months vs.32.8 months, P=0.204). And no significant differences in OS were found in patients with progression in liver(P=0.061).Conclusions: Crizotinib continuation together with local therapy might be a feasible strategy for patients with progression in brain beyond crizotinib resistance, as well as next-generation ALKi's. Next-generation ALKi's tended to provide a survival benefit in patients with non-liver progression. | Haiyan Xu Di Ma Guangjian Yang Junling Li Xuezhi Hao Puyuan Xing Lu Yang Fei Xu Yan Wang | 2019 | Chinese Journal of Cancer Research2019，31，2： | 6 |
| 9 | Innovations of phosphorus sustainability:implications for the whole chain显示文摘Phosphorus(P)is a non-renewable resource,therefore ensuring global food and environmental security depends upon sustainable P management.To achieve this goal,sustainable P management in the upstream and downstream sectors of agriculture from mineral extraction to food consumption must be addressed systematically.The innovation and feasibility of P sustainability are highlighted from the perspective of the whole P-based chain,including the mining and processing of P rock,production of P fertilizers,soil and rhizosphere processes involving P,absorption and utilization of P by plants,P in livestock production,as well as flow and management of P at the catchment scale.The paper also emphasizes the importance of recycling P and the current challenges of P recovery.Finally,sustainable solutions of holistic P management are proposed from the perspective of technology improvement with policy support. | Jianbo SHEN Liyang WANG Xiaoqiang JIAO Fanlei MENG Lin ZHANG Gu FENG Junling ZHANG Lixing YUAN Lin MA Yong HOU Tao ZHANG Weifeng ZHANG Guohua LI Kai ZHANG Fusuo ZHANG | 2019 | Frontiers of Agricultural Science and Engineering2019，6，4： | 4 |
| 10 | Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China显示文摘Objective:To identify serum biomarkers that may predict the short or long term outcomes of anti-Helicobacter pylori(H.pylori)treatment,a follow-up study was performed based on an intervention trial in Linqu County,China.Methods:A total of 529 subjects were selected randomly from 1,803 participants to evaluate total anti-H.pylori immunoglobulin G(Ig G)and 10 specific antibody levels before and after treatment at 1-,2-and 7.3-year.The outcomes of anti-H.pylori treatment were also parallelly assessed by 13C-urea breath test at 45-d after treatment and 7.3-year at the end of follow-up.Results:We found the medians of anti-H.pylori Ig G titers were consistently below cut-off value through 7.3years in eradicated group,however,the medians declined in recurrence group to 1.2 at 1-year after treatment and slightly increased to 2.0 at 7.3-year.While the medians were significantly higher(>3.0 at 2-and 7.3-year)among subjects who failed the eradication or received placebo.For specific antibody responses,baseline seropositivities of Fli D and Hpa A were reversely associated with eradication failure[for Fli D,odds ratio(OR)=0.44,95%confidence interval(95%CI):0.27–0.73;for Hpa A,OR=0.32,95%CI:0.17–0.60].The subjects with multiple positive specific antibodies at baseline were more likely to be successfully eradicated in a linear fashion(Ptrend=0.006).Conclusions:Our study suggested that total anti-H.pylori Ig G level may serve as a potential monitor of longterm impact on anti-H.pylori treatment,and priority for H.pylori treatment may be endowed to the subjects with multiple seropositive antibodies at baseline,especially for Fli D and Hap A. | Tianyi Wang Yang Zhang Huijuan Su Zhexuan Li Lian Zhang Junling Ma Weidong Liu Tong Zhou Weicheng You Kaifeng Pan | 2017 | Chinese Journal of Cancer Research2017，29，2： | 3 |
| 11 | Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?显示文摘Objective: Adjuvant chemotherapy(AC) after curative resection is known to improve the survival of patients with non-small cell lung cancer(NSCLC); however, few studies have reported the correlation between the time to initiation of AC(TTAC) and survival in NSCLC patients.Methods: The clinical data of 925 NSCLC patients who received curative resection and post-operative AC at the Cancer Hospital of Chinese Academy of Medical Sciences between 2003 and 2013 were retrospectively analyzed.TTAC was measured from the date of surgery to the initiation of AC. Disease-free survival(DFS) was defined as the duration from surgery to the time of tumor recurrence or last follow-up evaluation. The optimal cut-off value of TTAC was determined by maximally selected log-rank statistics. The DFS curve was estimated using the Kaplan-Meier method, and the Cox proportional hazards regression model was used to identify risk factors independently associated with DFS. Propensity score matching(PSM) was performed for survival analysis using the match data.Results: The optimal discriminating cut-off value of TTAC was set at d 35 after curative resection based on which the patients were assigned into two groups: group A(≤35 d) and group B(>35 d). There was no significant difference in the DFS between the two groups(P=0.246), indicating that the TTAC is not an independent prognostic factor for DFS. A further comparison continued to show no significant difference in the DFS among 258 PSM pairs(P=0.283).Conclusions: There was no significant correlation between the TTAC and DFS in NSCLC patients. Studies with larger samples are needed to further verify this conclusion. | Yutao Liu Xiaoyu Zhai Junling Li Zhiwen Li Di Ma Ziping Wang | 2017 | Chinese Journal of Cancer Research2017，29，3： | 2 |
| 12 | Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma显示文摘Mantle cell lymphoma(MCL)is a B-cell malignancy with poor clinical outcome and undefined pathogenesis.Development of clinically relevant cellular models for MCL research is an urgent need.Our preliminary observations lead the development of two novel hypotheses that we tested in this study:1.multicellular spheroid might be a unique growth mode of earlystage cells in MCL;2.MCL might be a polyclonal tumor.We made the following original observations that have not been reported:First,we have provided a new experiment method for enriching MCL early-stage cells and characterized the spheroid mode of growth as a unique feature of early-stage MCL cells in cell line as well as in clinical samples.Second,we have established a clinically relevant cellular model of MCL,the JeKo-1-spheroid cell line,that was highly enriched in early-stage sub-clones.JeKo-1-spheroid cells and the spheroid growing cells enriched from MCL patients exhibited comparably enhanced tumorigenic abilities and similar biological features.Third,Immunophenotypic analysis has revealed that MCL may be derived from precursor-B(pre-B),immature-B and mature-B cells,not only the mature-B cells as WHO classified in 2016.Fourth,MCL may be a polyclonal disease composed of CD19e/IgMe,CD19 e/IgMt,CD19t/IgMt three sub-clones,of which the CD19e/IgMt sub-clone might be the dominant sub-clone with the strongest tumorigenic ability.Fifth,CD19t/IgMe that differentiates MCL and normal B cells may represent a new marker for MCL early detection,minor residual disease monitoring after therapies and prognosis. | Junling Tang Li Zhang Tiejun Zhou Zhiwei Sun Liangsheng Kong Li Jing Hongyun Xing Hongyan Wu Yongli Liu Shixia Zhou Jingyuan Li Mei Chen Fang Xu Jirui Tang Tao Ma Min Hu Dan Liu Jing Guo Xiaofeng Zhu Yan Chen Ting Ye Jianyu Wang Xiaoming Li H.Rosie Xing | 2019 | Genes & Diseases2019，6，4： | 2 |
| 13 | 2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy显示文摘Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia are at an increased risk for life-threatening obstetric complications.Therefore,we established this consensus statement on the diagnosis and management of ITP during pregnancy(detailed information is available in the Supplementary File,http://gffzz16e312a87a7141a5huu6kvpckqcqx6b6k.ffgz.tsg.suse.edu.cn/A978). | Zhang Xiaohui Chen Fangping Chen Xiequn Cheng Yunfeng Fang Meiyun Feng Jianming Fu Haixia Gao Hong Han Yue He Aili Hou Ming Hu Yu Huang Ruibin Huang Wenrong Jing Zhicheng Kong Peiyan Liang Aibin Liang Meiying Liu Daihong Liu Junling Liu Lin Liu Xiaowei Ma Liangming Mei Heng Ni Heyu Niu Ting Peng Jun Qiao Jianlin Ren Jinhai Song Yongping Tang Liang V Tong Tong Wang Shaoyuan Wang Xin Wang Zhao Wei Hui Wu Depei Wu Guangsheng Xu Caigang Xu Xue Xu Yajing Yang Linhua Yang Renchi Yang Tonghua Yin Chenghong Yu Li Zhang Guangsen Zhang Lei Zhang Liansheng Zhang Xi Zhao Weili Zhao Yongqiang Zhou Daobin Zhou Hu Zhou Zeping Zhu Tienan Wang Jianliu Huang Xiaojun | 2022 | Chinese Medical Journal2022，，8： | 2 |
| 14 | Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study显示文摘Objective: Crizotinib has demonstrated promising efficacy in patients with anaplastic lymphoma kinase(ALK)-positive non-small-cell lung cancer(NSCLC) in clinical trials. We conducted this retrospective multicenter study to assess the outcomes of crizotinib therapy in, to our knowledge, a large sample cohort of patients with ALKpositive advanced NSCLC.Methods: We reviewed the medical records of 484 unselected ALK-positive NSCLC patients treated with crizotinib at 5 cancer centers in China from January 2013 to November 2017. Clinical data were collected from the initiation of crizotinib therapy to Response Evaluation Criteria in Solid Tumors(RECIST)-defined progressive disease(PD).Results: A total of 428 eligible ALK-positive NSCLC patients were enrolled, 273(63.8%) of whom received crizotinib as first-line treatment. The median progression-free survival(PFS) and overall survival(OS) from the initiation of crizotinib treatment were 14.4 [95% confidence interval(95% CI), 12.4-16.4] months and 53.4(95%CI, 33.7-73.1) months, respectively. In subgroup analyses, patients who received crizotinib as first-line treatment showed a higher disease control rate(DCR) and a longer median OS compared with second-/later-line crizotinib treatment(94.8% and OS not reached vs. 89.0% and 40.5 months, respectively). For 261 patients with RECISTdefined PD, multivariate Cox analysis revealed that in patients who received first-line crizotinib therapy, continued crizotinib beyond progressive disease(CBPD) and next-generation ALK inhibitors after crizotinib failure were associated with improved survival.Conclusions: This study has demonstrated the clinically meaningful benefit of crizotinib treatment in a large cohort of Chinese ALK-positive NSCLC patients. CBPD and next-generation ALK inhibitor treatment may provide improved survival after RECIST-defined progression on crizotinib. | Puyuan Xing Di Ma Qiang Wang Xuezhi Hao Mengzhao Wang Yan Wang Li Shan Tao Xin Li Liang Hongge Liang Yang Du Zhaohui Zhang Junling Li | 2019 | Chinese Journal of Cancer Research2019，31，3： | 2 |
| 15 | Buxus Leaves from the Oligocene of Guangxi, China and Their Biogeographical Significance显示文摘The present paper reports two new species of Buxus from the Oligocene Ningming Formation of Guangxi, South China, on the basis of several compressed fossil leaves.Buxus ningmingensis sp.nov.is characterized by an elliptic to ovate shape; pinnate venation with marginal secondary, long hairs on the adaxial side of the midvein base; and amphistomatic, anomocytic stomata with a prominent outer ring.All of these characteristics suggest a closest affinity to the living Buxus microphylla subsp.sinica.Another new species identified as Buxus preaustro-yunnanensis sp.nov.is characterized by the diagnostic formation of its admedially branched tertiaries, the trunks of which are often strongly thickened by sclereides.This species is most similar to the extant Buxus austroyunnanensis.The co-occurrence of Buxus ningmingensis sp.nov.and Buxus preaustro-yunnanensis sp.nov.suggests that these two Buxus lived during the Oligocene under a warm, tropical to subtropical climate, similar to the current climate of Ningming.Our findings provide the earliest fossil evidence of Buxus leaves with detailed illustrations of leaf architectural and cuticular features.The occurrence of these two species indicates that Buxus began to diversify in Guangxi no later than the Oligocene. | MA Fujun WANG Qiujun DONG Junling YANG Yi WANG Wenjia YAN Defei SUN Bainian | 2015 | Acta Geologica Sinica(English Edition)2015，89，5： | 2 |
| 16 | Amino acid extraction with AOT reversed micelle显示文摘 | Fu Xun Li Junling Ma Ying | 2001 | Colloids and Surfaces2001，179，： | 1 |
| 17 | Amino acid extraction with AOT reverse micelle显示文摘 | Fu Xun Li Junling Ma Ying | 2001 | Colloids and Surfaces A:Physicochemical and Engineering Aspects2001，179，： | 1 |
| 18 | Generality of the Final Size Formula for an Epidemic of a Newly Invading Infectious Disease显示文摘 | Junling Ma David J. D. Earn | 2006 | Bulletin of Mathematical Biology2006，，3： | 1 |
| 19 | Study on open-cycle carbon dioxide refrigerator for movable mine refuge chamber显示文摘 | Yang Junling Yang Luwei Wei Juan Ma Yuezheng Zhang Zhentao | 2012 | Applied Thermal Engineering2012，，： | 1 |
| 20 | Genetic Variants in Cyclooxygenase-2 : Expression and Risk of Gastric Cancer and Its Precursors in a Chinese Population显示文摘 | Fen Liu Kaifeng Pan Xuemei Zhang Yang Zhang Lian Zhang Junling Ma Caixuan Dong Lin Shen Jiyou Li Dajun Deng Dongxin Lin Weicheng You | 2006 | Gastroenterology2006，，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员